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Abstract
Background. There is growing evidence of genetic risk for
susceptibilitytoIgAnephropathy.Amongseveralcandidate
genes related to immunological regulation in renal tissue,
TGFB1 isknown tobeacontributor toproliferationand the
development of fibrosis.
Methods.WeanalysedseveralSNPsinaregionofthisgene
using212DNAsamplesfrombiopsy-provenIgAnephropa-
thy patients, 146 men and 66 women and 477 healthy age-
matched controls (321 men and 156 women) from the same
population in Sweden.
Results. Frequencies of four out of five selected SNPs
(rs6957,rs2241715,rs1800471,rs1982073andrs1800469)
werefoundtosignificantlydifferbetweenmalepatientsand
male controls in a co-dominant model (corrected P ≤ 0.05)
and of two SNPs (rs1982073 and rs1800469) in the allelic
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model (P ≤ 0.05 in 100000 permutation test). Haplotype
analysis for five selected SNPs revealed a significant as-
sociation of TGGCG with protective effect (P = 0.0012,
empirical P = 0.006, 100000 permutations) and of CT-
GTA with susceptibility effect (P = 0.0018, empirical P =
0.008, 100000 permutations). In our study, no association
with TGFB1 variations was found when comparing female
patients and female controls. No association was found for
TGFB1 markers with disease progression for selected indi-
viduals from the patient’s group. In addition, meta-analysis
performed for SNP rs1982073 for combined patients and
controls from our study together with published data from
two independent studies showed a significant association.
Conclusions. Our experimental data together with the
meta-analysis suggest TGFB1 as an important candidate
gene for further biological studies of IgA nephropathy and
as a possible target for therapy. Our data also indicate a
possibility of a gender effect in the genetic background of
IgA nephropathy.
Keywords: IgA nephropathy; polymorphism; SNP; TGFB1
Introduction
IgA nephropathy is the most common form of glomeru-
lonephritisidentifiedinallregionsoftheworldwhererenal
biopsy is widely practiced. Evidence derived from experi-
mentalmodelsofspontaneousIgAnephropathyandstudies
of the genetics, familial occurrence and racial differences
in prevalence support the influence of genetic factors in the
development and progression of IgA nephropathy [1–3].
IgA nephropathy in Caucasian populations was shown to
bemoreprevalentinmen;theratioofmalestofemaleswith
IgA nephropathy is around 6:1 in northern Europe and the
United States [4]. Poor prognostic factors for progression
of renal damage in patients with IgA nephropathy are male
gender, older age, presence of hypertension, moderate or
severe proteinuria and severe renal lesions [1].
Transforming growth factor-β1( T G F β1) is a multifunc-
tional cytokine that mediates cell proliferation, differen-
tiation and other functions in different cell types. TGFβ1
signallingisanessentialmechanisminisotypeswitchingto
immunoglobulin A in B lymphocytes and up-regulates IgA
production in general [5]. TGFβ1 contributes to the expan-
sion of mesangial matrix, development of fibrosis and cell
proliferation both in animal models and in human diseases
[6,7]. The kidney seems to be particularly sensitive to the
powerful fibrogenic actions of TGFβ1 that may contribute
to fibrosis in most forms of renal diseases, leading to renal
impairment and decreased renal function [8,9].
The TGFβ1 gene, TGFB1, is located at the human chro-
mosome 19q13.1-3 (omim 190180). There are several in-
dications that genetic polymorphism of this gene is in-
volved in the development of fibrotic diseases [8,10,11]
and may regulate TGFβ1 production [12]. Four previous
studies of TGFB1 polymorphisms have demonstrated pos-
sible associations between susceptibility and/or severity of
IgA nephropathy, but the results have so far been inconsis-
tent [9,10,13,14].
In the present study, 212 unrelated patients with biopsy-
proven IgA nephropathy and 477 healthy subjects were se-
lected for studies of five various polymorphisms in the
TGFB1 gene with consideration to gender. In addition, a
meta-analysis including previous studies was performed in
order to clarify the role of TGFβ1 as a possible susceptibil-
ity factor in IgA nephropathy.
Materials and methods
Subjects
A total of 212 unrelated patients (146 males and 66 females), mean age
38.5 ± 14.4 (range 17–77 years) with biopsy-proven IgA nephropathy,
all self-reported Caucasians, and 477 individually sex- and age-matched
healthy Caucasians from a Swedish population (321 males and 156 fe-
males), mean age 44.8 ± 13.0 (range 18–80 years), were included in the
present investigation. The patients were recruited from the Department of
Nephrology at the Karolinska University Hospital (n = 117), Danderyd
Hospital (n = 31), Sk¨ ovde Hospital (n = 36) and Link¨ oping Hospital (n
= 28), representing a population from the central part of Sweden. Patients
with Henoch-Sch¨ onlein purpura and other forms of glomerulonephritis
were not included in the study. For known information about kidney func-
tion in the patients at the time of diagnosis, see Table 1.
All patients gave informed consent, and the study was approved by the
Ethics Committee of the Karolinska Hospital, Stockholm, Sweden.
Disease severity
One hundred and seventeen patients from the Karolinska University Hos-
pital, who had been followed up for up to 12 years since renal biopsy,
were investigated for the correlation between TGFB1 genotype and dis-
ease severity. The average age of these patients at the time of renal biopsy
was 37.0 ± 13.2 years (range 17–77 years).
Glomerular filtration rate (GFR) was estimated from yearly serum
creatinine measurements using the Modification of Diet in Renal Disease
(MDRD) equation [15]. To investigate the correlation between genotype
and disease severity, we used the following criteria: for benign disease,
loss of GFR of <2 ml/min/year, for moderate progression loss of GFR of
≥2t o<5ml/min/year or theprogression to chronickidney disease (CKD)
stage 3 (GFR = 30–59 ml/min/1.73 m2), and for severe progression, loss
of GFR of ≥5 ml/min/year or reaching CDK stage 4 or 5 (GFR = 15–29
ml/min/1.73 m2 and GFR<15 ml/min/1.73 m2).
Selection of markers
The TGFB1 gene in the HapMap database represents a sequence at
chromosome 19q13.1 between two recombination blocks. We succeeded
Table 1. Glomerular filtration rate of the patients in the different stages of chronic kidney diseasea
>90 ml/min 90–60 ml/min 30–59 ml/min 15–29 ml/min <15 ml/min
Males, n = 77 (73.3%) 19 (18.1%) 28 (26.7%) 20 (19.0%) 6 (5.7%) 4 (3.8%)
Females, n = 28 (26.7%) 4 (3.8%) 15 (14.3%) 6 (5.7%) 2 (1.9%) 1 (1%)
Total, n = 105 (100%) 23 (21.9%) 43 (41.0%) 26 (24.7%) 8 (7.6%) 5 (4.8%)
aCalculated for individuals with available clinical data.TGFB1 genetics of IgA nephropathy 3063
Table 2. Polymorphisms of the TGFB1 gene in IgA nephropathy patients
Chromosome Heterozygosity
SNP Position Alternative name position Alleles from NCBI MAFa ABI assay Methods
rs6957 Downstream 3 
genomic region
46522446 C/T 0.414 0.167 C___7818385_10 TaqMan
rs2241715 Intron 1 46548726 G/T 0.467 0.289 Assay by design TaqMan
rs1800471 Signal sequence of
exone 1
Codon 25 or G915C
(arginine→proline)
46550716 C/G 0.112 0.081 NA REMb
rs1982073 Signal sequence of
exone 1
Codon 10 or T869C
(leucine→proline)
46550761 C/T 0.397 0.378 C___22272997_10 TaqMan
rs1800469 Promoter C-509T 46552136 A/G 0.485 0.295 C___8708473_10 TaqMan
aMinor allele frequency from current study.
bRestriction Endonuclease Mapping method.
with five reproducible assays: in the promoter region at position −509,
rs1800469 (C-509T), in the downstream 3  genomic region, rs6957, in the
intron, rs2241715, and two in the signal sequence of exon 1, rs1800471
(C915G or codon 25, arginine→proline) and rs1982073 (T869C or codon
10, leucine→proline). More detailed information of all selected SNPs
with the minor allele frequencies is presented in Table 2.
DNA and genotyping
DNA was extracted from EDTA blood samples (5–10 ml) by the ‘salting
out’ method as described elsewhere [16]. To identify codon 25 allele poly-
morphism (rs1800471) in the TGFB1 gene, the restriction endonuclease
mapping method (REM) was used as previously described [16]. To detect
other SNPs (rs6957, rs2241715, rs1982073 and rs1800469) of the TGFB1
gene, the TaqMan allelic discrimination assay (Applied Biosystems, Fos-
ter City, CA, USA) was used. Three out of four assays were commercially
available and one was designed for this project (Table 2). TaqMan allelic
discrimination was performed according to the standard protocol in a 384-
well plate with 10 ng of DNA per sample. PCR was run in GeneAmp PCR
System 9700 (Applied Biosystems), and the fluorescent signals from the
hybridizationprobesweredetected bya7900SequenceDetector (Applied
Biosystems).
To assess genotyping robustness, we re-genotyped a random subset of
191casesandcontrolsforrs1982073SNPusingtherestrictionendonucle-
ase mapping method published previously [17], which resulted in a 99.5%
match of genotyping calls with the TaqMan assay.
All analysed markers were in Hardy–Weinberg equilibrium. Positive
rates of genotype detection were 99.9% for rs2241715, 99.3% for rs6957
and 99.6% for the rest of the SNPs.
Statistical analysis
Toassessgenotype,alleleandhaplotypefrequencies,Pearson’schi-square
and/or Fisher’s exact tests were performed when appropriate with SPSS
13.0software.HaplotypeanalysiswascarriedoutbyHaploView[18],and
the permutation test of this analysis was set to 100000 permutations for
single markers and haplotypes. For meta-analysis, the Mantel–Haenszel
method was employed with a fixed effect and 95% confidence interval
(95% CI) for odds ratio. Power calculation was performed for the two-
tailedorone-tailedtestwhenappropriatefor5%thresholdofsignificance.
Results
Genotype frequencies of TGFB1 polymorphisms in male
and female IgA nephropathy patients and healthy controls
Wegenotyped212unrelatedIgAnephropathypatients,146
men (68.9%) and 66 women (31.1%), and 477 healthy sub-
jects, 321 men (67.3%) and 156 women (32.7%), for five
various polymorphisms of the TGFB1 gene. The minor al-
lelic frequencies (MAF) are presented in Table 2. A signif-
icant difference between the genotype distribution in male
IgA nephropathy patients and male healthy controls was
found in a co-dominant model for all five SNPs (Table 3a).
After the Bonferroni correction for multiple comparisons,
four out of five SNPs remained significantly associated
with P ≤ 0.05. Genotype frequencies for studied SNPs in
the female studygroup did not, however, show asignificant
difference (Table 3b).
The allele and haplotype frequencies with experimental
chi-square P-values and empiric P-values after permuta-
tion test are presented in Tables 4 and 5. When comparing
the frequency of alleles, we found significant differences
for rs2241715, rs1982073 and rs1800469 comparing male
patients and male controls (P < 0.02, Table 4a). To check
forpossiblefalsepositiveassociations,weperformedaper-
mutationtestwith100000permutationssimultaneouslyfor
single markers and haplotypes, which resulted in empiric
P = 0.04 and P = 0.02 for rs1800469 and rs1982073,
respectively. A relatively high degree of linkage disequi-
librium (LD) was detected in this locus, which resulted
in 5 observed out of 32 expected haplotypes, which made
it relatively easy to reveal genetic variability with the se-
lected number of SNPs. Two out of five marker haplotypes,
TGGCG and CTGTA, showed a significant difference be-
tweenmalepatientsandmalecontrols(P=0.0012andP=
0.0018, respectively, Table 5a), and these two haplotypes
passed the permutation test with empiric P = 0.006 and
0.008, respectively. These haplotypes represent either pro-
tective (TGGCG) or susceptible (CTGTA) variants and are
opposite in four out of five alleles. The protective TGGCG
haplotype comprises 56.4% of all chromosomes in the con-
trol male population and the CTGTA represents only 5.7%.
The former number corresponds to 90% and the latter to
86% power of analysis to detect significant difference at
0.05 threshold in the two-tailed test. We found no indica-
tion for an association of TGFB1 gene polymorphism with
disease in females in the allelic model nor in the haplotype
analysis for this study group (Tables 4b and 5b).
Correlations between genotypes and progression of IgA
nephropathy
Using the disease severity criteria defined in the ‘Mate-
rials and methods’ section in 95 patients with available3064 M. T. Vuong et al.
Table 3. Genotype frequencies of TGFB1 polymorphisms in (a) male and (b) female IgA nephropathy patients in a co-dominant model
SNPs Genotype frequency in co-dominant model Chi-square P-valuea
(a) Male IgA nephropathy patients
TGFB1 rs6957 Totalb CC CT TT
Group Control 314 (100%) 3 (1%) 85 (27%) 226 (72%) 11.5 0.003
Patient 144 (100%) 9 (6.3%) 42 (29.1%) 93 (64.6%)
TGFB1 rs2241715 Total GG GT TT
Group Control 315 (100%) 171 (54.3%) 120 (38.1%) 24 (7.6%) 7.4 0.02
Patient 145 (100%) 59 (40.7%) 73 (50.3%) 13 (9%)
TGFB1 rs1800471 Total CC CG GG
Group Control 319 (100%) 0 (0%) 48 (15%) 271 (85%) 9.1 0.01
Patient 143 (100%) 4 (2.8%) 19 (13.3%) 120 (83.9%)
TGFB1 rs1982073 Total CC CT TT
Group Control 314 (100%) 132 (42%) 147 (46.8%) 35 (11.2%) 9.9 0.007
Patient 144 (100%) 40 (27.8%) 78 (54.2%) 26 (18%)
TGFB1 rs1800469 Total AA AG GG
Group Control 314 (100%) 24 (7.6%) 120 (38.2%) 170 (54.2%) 10.2 0.006
Patient 144 (100%) 13 (9%) 76 (52.8%) 55 (38.2%)
(b) Female IgA nephropathy patients
TGFB1 rs6957 Totalb CC CT TT
Group Control 152 (100%) 4 (2.6%) 44 (28.9%) 104 (68.5%) 0.9 0.6
Patient 65 (100%) 3 (4.6%) 16 (24.6%) 46 (70.8%)
TGFB1 rs2241715 Total GG GT TT
Group Control 153 (100%) 75 (49%) 64 (41.8%) 14 (9.2%) 1.4 0.5
Patient 66 (100%) 35 (53%) 28 (42.4%) 3 (4.6%)
TGFB1 rs1800471 Total CC CG GG
Group Control 156 (100%) 0 (0%) 23 (14.7%) 133 (85.3%) 2.4 0.3
Patient 66 (100%) 1 (1.5%) 10 (15.2%) 55 (83.3%)
TGFB1 rs1982073 Total CC CT TT
Group Control 153 (100%) 56 (36.6%) 78 (51%) 19 (12.4%) 0.3 0.8
Patient 66 (100%) 26 (39.4%) 31 (47%) 9 (13.6%)
TGFB1 rs1800469 Total AA AG GG
Group Control 154 (100%) 14 (9.1%) 65 (42.2%) 75 (48.7%) 0.5 0.8
Patient 65 (100%) 4 (6.2%) 28 (43%) 33 (50.8%)
aUncorrected.
bTotal number for different variations may be different due to genotyping failure.
Table 4. Allelic frequencies of TGFB1 polymorphisms in (a) male and (b) female IgA nephropathy patients and healthy controls
Control, case Control, case 100000 permutation,
SNPs ratio counts frequencies Chi-square P-valuea P-value
(a) Male IgA nephropathy patients
rs6957 537:91, 228:60 0.855, 0.792 5.77 0.016 0.08
rs2241715 462:168, 191:99 0.733, 0.659 5.381 0.020 0.09
rs1800471 581:47, 259:27 0.925, 0.906 1.011 0.314 NS
rs1982073 411:217, 158:130 0.654, 0.549 9.401 0.002 0.02
rs1800469 460:168, 186:102 0.732, 0.646 7.132 0.007 0.04
(b) Female IgA nephropathy patients
rs6957 52:252, 22:108 0.171, 0.169 0.002 0.9631 NS
rs2241715 92:214, 34:98 0.301, 0.258 0.835 0.3608 NS
rs1800471 285:23, 120:12 0.925, 0.909 0.333 0.5641 NS
rs1982073 116:190, 49:83 0.379, 0.371 0.024 0.876 NS
rs1800469 93:215, 36:94 0.302, 0.277 0.276 0.5996 NS
aUncorrected.
clinical data, 52 (54.7%) patients were classified as having
benign disease, 19 (20%) patients had moderate renal dis-
ease progression and 24 (25.3%) patients had severe renal
disease progression. No significant differences in genotype
frequencies in either the co-dominant model or the dom-
inant/recessive model were observed among the different
severity groups with or without stratification for gender
(data not shown).
Meta-analysis
By searching information from PubMed and ISI Web
of Knowledge, we found four published articles related
to TGFB1 gene polymorphisms in IgA nephropathy in
four different populations: Korean, Japanese, Italian and
German [9,10,13,14]. No additional data were found in
abstracts or proceedings. All papers had used similar selec-
tion criteria for IgA nephropathy patients compared to ourTGFB1 genetics of IgA nephropathy 3065
Table 5. Haplotype frequencies of TGFB1 polymorphisms in (a) male and (b) female IgA nephropathy patients and healthy controls
Haplotype Control/case 100000 permutation
Block frequencies Control/case ratio counts frequencies Chi-square P-valuea P-value
(a) Male IgA nephropathy patients
TGGCG 0.528 355.5: 274.5, 130.5: 159.5 0.564, 0.450 10.42 0.0012 0.006
TTGTA 0.214 131.1: 498.9, 65.5: 224.5 0.208, 0.226 0.374 0.5411 NS
CGGCG 0.089 55.5: 574.5, 26.5: 263.5 0.088, 0.091 0.026 0.8709 NS
TGCTG 0.080 47.0: 583.0, 27.0: 263.0 0.075, 0.093 0.919 0.3378 NS
CTGTA 0.075 35.9: 594.1, 33.5: 256.5 0.057, 0.116 9.749 0.0018 0.008
(b) Female IgA nephropathy patients
TGGCG 0.526 161.8: 146.2, 69.6: 62.4 0.525, 0.527 0.001 0.9709 NS
TTGTA 0.220 69.4: 238.6, 27.2: 104.8 0.225, 0.206 0.194 0.6599 NS
CGGCG 0.092 27.2: 280.8, 13.4: 118.6 0.088, 0.101 0.194 0.6595 NS
TGCTG 0.070 19.8: 288.2, 10.9: 121.1 0.064, 0.082 0.455 0.4998 NS
CTGTA 0.064 21.6: 286.4, 6.8: 125.2 0.070, 0.051 0.545 0.4602 NS
aUncorrected.
Fig. 1. Meta-analysis with rs1800469 in two different populations and our own data; the genetic marker displayed a protective effect for the common
genotype with CC and passed test for heterogeneity between the studies.
study; however, selection of control groups differed from
ourstudyandstratificationforgenderwasnotdone.Onlyin
the study by Carturan et al., the control group was age- and
gender-matched. In the study of Bantis et al., controls were
matched by age, but not by gender. In the studies by Sato
et al. and Lim et al., the control groups were discordant for
ageandforgenderratio.AllstudiesexceptthatbyCarturan
et al. reported that individuals in the control groups were of
thesameethnicityasthepatientgroups.AtleasttwoTGFB1
polymorphisms (rs1982073 and rs1800469) were investi-
gated in three studies [9,10,13]. Two studies [10,13] were
included in meta-analysis together with our data for these
TGFB1 markers. In the remaining study [9], the frequency
of the genotype distribution for the rs1982073 significantly
deviated from Hardy–Weinberg equilibrium, which ques-
tions the validity of the data. For this reason, we decided
to exclude this particular study from the meta-analysis. As
we could only use the frequency of variations for the com-
bined group of both genders in the previously published
studies, our own data were also not stratified by gender
for the meta-analysis. The Mantel–Haenszel method with
fixed effect demonstrated a significant cumulative odds ra-
tio for rs1982073 (0.77, 95% CI 0.61–0.97) (Figure 1),
suggesting that the TGFB1 gene polymorphism is associ-
ated with IgA nephropathy in the studied populations. In
addition, rs1800469 showed a trend for association with
disease susceptibility, which did not reach statistical sig-
nificance in the meta-analysis (0.86, 95% CI 0.69–1.07).
Both genetic markers displayed a protective effect for the
common genotype (CC and GG respectively) and passed
the test for heterogeneity between the studies.
Discussion
In the present study, we demonstrate an association of the
TGFB1 gene polymorphism with IgA nephropathy. Our
own data, together with the meta-analysis of previously
published data, provide a strong indication of the impor-
tance of TGFβ1 in the development of IgA nephropathy.
Previously, both linkage and association studies have
been utilized to study the susceptibility risk factors for
IgA nephropathy. Using genome-wide linkage microsatel-
lite analysis, a linkage of IgA nephropathy to 2q36, 6q22–
23, 4q26–31 and 17q12–22 has been suggested [3,19–22].
However, no obvious candidate genes within these link-
age regions have so far been identified. Several candidate
gene polymorphism association studies have previously
been performed to explore the role of several genes that
could be related to the susceptibility to and the progression
of IgA nephropathy, including MHC class II [23], T-cell
receptor α and β [24–26], uteroglobin [27,28], angiotensin-3066 M. T. Vuong et al.
converting enzyme (ACE) [29,30], other renin–angiotensin
system genes [31,32], as well as several cytokine genes
[33].However,someofthesestudieshaveshowncontradic-
tory results, and larger patient populations with an optimal
study design are required to establish the role of specific
genes in the susceptibility to IgA nephropathy. Although
most studies used ethnically homogeneous study popula-
tions, the gender effect was not assessed in any of those
investigations.
In our analysis of five TGFB1 gene polymorphisms in a
cohort of 212 patients with IgA nephropathy and 477 age-,
gender- and ethnicity-matched controls, we were able to
demonstrate, with reasonable statistical power, an associa-
tion between genetic variations in the TGFB1 gene and the
susceptibilitytoIgAnephropathyinmales.Ameta-analysis
of previously published data from two independent studies
together with our results strengthens this conclusion.
There are four previous studies addressing the impor-
tance of the TGFB1 gene in IgA nephropathy in four differ-
ent populations [9,10,13,14]. In the study performed in 329
Japanese patients with IgA nephropathy, two TGFB1 gene
polymorphisms (rs1982073 and rs1800469) were shown to
associate with heavy proteinuria and mesangial glomerular
proliferation. This is at the moment the largest published
genetic study of IgA nephropathy. However, no associa-
tion with susceptibility to IgA nephropathy was demon-
strated [10]. In the study from South Korea, analysing two
SNPs, C-509T and T869C (rs1982073 and rs1800469),
a significant difference in the genotype frequency was
found comparing 108 patients with IgA nephropathy and
healthy controls [9]. Since the reported frequencies of the
rs1800469 genotypes significantly deviated from Hardy–
Weinberg equilibrium, these data have to be taken with
some caution. Two other studies were done in Europe in
Caucasians with IgA nephropathy. In the study performed
in Germany, one TGFB1 SNP, rs1800471 (C915G or codon
25, arginine→proline), showed the similar genotype dis-
tribution between IgA nephropathy patients and controls
as well as between the progression and non-progression
groups [14]. Finally, in an Italian study, three TGFB1
SNPs, Leu10→Pro (rs1982073), C-509T (rs1800469) and
G-800A(rs1800468),wereinvestigatedin101patientswith
IgA nephropathy and 118 healthy controls [13]. A signif-
icant association was observed in the haplotype analysis,
but genotype frequencies did not reach significant statisti-
cal difference.
Three previous studies have demonstrated either a ten-
dency for an association or a significant association with
at least some genetic markers in the TGFB1 gene. We per-
formed a meta-analysis in order to further test the role
of TGFB1 in the susceptibility to IgA nephropathy. In the
meta-analysis,wecombinedournewfindingsanddatawith
those obtained in two of the previously published studies
[10,13] and included two genetic markers (rs1982073 and
rs1800469) that were investigated in all of the studies. Due
to the fact that data in previous studies could not be strat-
ified by gender, we combined the female and male groups
in our study into one group for this specific test. This meta-
analysis supported the role of the TGFB1 gene in the de-
velopment of IgA nephropathy in a combined group of 640
IgA nephropathy patients and 880 controls with a post hoc
powerestimateof96%fortheone-tailedtest.However,this
must be taken with caution due to a possible bias towards
publishing of positive associations. It is also important to
perform further extension of the study to get better statisti-
cal power to detect an association. Another way of address-
ing a lack of power could be replication of the association
in independent cohorts.
However, it is possibly premature to claim functional
consequences from any of the analysed variations, due to
a strong pattern of LD in this region. In fact, three mark-
ers from our study (rs1800469, rs1982073 and rs1800471)
belong to the recombination block with high LD (D ≈1.0),
which means that any variation in this region may be in
association with a certain phenotype, because of its close
position to the mutual causal allele. This is a strong indi-
cation of either a true importance of the combination of
common alleles, which were selected for our study, or for
an unknown causal variation, which is in high LD with the
analysed single-nucleotide polymorphisms (SNPs). In both
cases, it is evident that genetic variations in the TGFB1 lo-
cuscouldbeimportantcontributorstodiseasedevelopment.
It is also noteworthy to mention that the genetic landscape
of variations in this locus seems to be very different in
Caucasian and Chinese or Japanese populations and allelic
frequencies are significantly different [34,35]. This must
be taken into account in future studies of different patient
populations. We excluded non-Caucasians from the current
study to avoid extensive population admixture, but a proper
genomic control in our study was not possible due to the
limited number of included SNPs. Another potential dif-
ficulty is the failure in genotyping of some variations in
this locus: out of nine tested SNP assays only four demon-
strated a robust performance and were selected for our ge-
netic study, which may illustrate either a high homology of
sequences flanking these variations with other genetic re-
gions or a high frequency of copy number polymorphisms
in this locus.
In our study, no significant differences in genotype fre-
quencies between the non-progression and the progression
groups of IgA nephropathy patients with impaired renal
function could be demonstrated.
In summary, by using our own experimental data and
a meta-analysis of previously published data, we propose
that the TGFB1 gene is an important contributor for the
susceptibility to IgA nephropathy. Additional replication
for such association and further studies are warranted to
investigate disease mechanisms and the physiological role
ofTGFB1inthedevelopmentofkidneydiseases.Moreover,
we suggest considering the effect of gender in such studies.
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